# A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

> **NCT06073860** · — · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 104 (estimated)

## Conditions studied

- Myelodysplastic Syndrome
- Beta Thalassemia

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT06073860
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-25
- **Primary completion:** 2027-12-21
- **Final completion:** 2027-12-21
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06073860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06073860, "A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06073860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*